---
title: CDMO Daily News — June 9, 2026
slug: daily-news-2026-06-09-cdmo
site: cdmo
post_kind: news
byline: BioBM
last_updated: 2026-06-09T05:17:09.193Z
---

* **Cell & Gene Therapy CDMOs Address Manufacturing Complexity and Capacity Gaps** — CGT market projected to reach $143.6 billion by 2034 (31% CAGR), driving demand for specialized manufacturing and supply-chain solutions.
  - Sponsors engage CDMOs earlier in development to access GMP infrastructure, regulatory expertise, and modality-specific capabilities—particularly for RNA/LNP therapies and autologous cell therapies.
  - CDMOs offer risk reduction, supply-chain resilience, and process knowledge preservation during ownership transitions and scale-up to commercial production.
  *Operational Impact:* Sponsors are shifting outsourcing decisions toward CDMOs with multi-site global networks and specialized expertise in complex modalities (AAV, autologous cell, in-vivo CAR-T); [AGC Biologics](/companies/agcbio) and [Andelyn Biosciences](/companies/andelynbio) highlight the competitive advantage of modality-specific technical depth and supply-chain continuity.
* **Single-Site Operations and Integrated Teams Reduce CDMO Partnership Risk** — Multi-site CDMOs with fragmented handoffs and siloed teams amplify risk through communication gaps and knowledge loss across development phases.
  - Purpose-built single-site facilities like Upperton's Trent Gateway maintain continuous program teams and technical memory from research through GMP manufacturing.
  - Integrated project management embedded within scientific execution enables proactive risk identification rather than reactive problem-solving.
  *Operational Impact:* Biotech sponsors evaluating CDMO partners should prioritize single-site operations with co-located development and manufacturing teams, as Upperton's model demonstrates how facility design and team continuity directly reduce timeline delays and deviation risk.

## References

1. [Contract Pharma RSS — Cell & Gene Therapy CDMOs Address Manufacturing Complexity and Capacity Gaps](https://www.contractpharma.com/cell-gene-therapy-cdmo-partnerships)
2. [Contract Pharma RSS — Single-Site Operations and Integrated Teams Reduce CDMO Partnership Risk](https://www.contractpharma.com/risk-isnt-inevitable-how-the-right-cdmo-partnership-protects-your-program)

Source: https://cdmo.directory/posts/daily-news-2026-06-09-cdmo